Singapore: HUYA Bioscience International has entered into a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development and Shanghai Pharma Engine. The new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.

HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China.

HUYA has also established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Founded in 1996 and supported jointly by the Ministry of Science and Technology, the Ministry of Health, SFDA, Chinese Academy of Sciences and Shanghai Municipal Government, Zhangjiang Biotech Pharmaceutical Base focuses on the development of innovations in biotechnology and pharmaceutical industries.

The partnership will enable HUYA and Zhangjiang Biotech Pharmaceutical Base to collaborate on promoting new drug development worldwide. Zhangjiang Biotech Pharmaceutical Base will be able to consult with HUYA's team of experts in drug development and globalization. In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at Zhangjiang Biotech Pharmaceutical Base and provide support and assistance as needed.

"HUYA is delighted to work with the prestigious Zhangjiang Biotech Pharmaceutical Base in a partnership that aims to advance the global development of innovative pharmaceutical products from China," said Mr Clement Gingras, HUYA's chief technical officer and COO, China. "We are
very excited about this partnership and look forward to fruitful collaborations in the years to come."